3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Aelix Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study) Vaccine + extension of the ATI period, Placebo + extension of the ATI period - HIV-1 Infection | Phase 1 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 6 | 2020-06-01 | 2022-05-04 |
| Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients ChAdOx1.HTI, MVA.HTI, GS-9620 - HIV/AIDS | Phase 2 | Completed | Aelix Therapeutics | 50 | 2020-02-20 | 2023-07-27 |
| Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002) DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM), At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM), Placebo - HIV | Phase 1 | Completed | Aelix Therapeutics | 45 | 2017-07-07 | 2021-04-08 |
HIV Infections (2) · Acquired Immunodeficiency Syndrome (1)
Vaccines (1) · vesatolimod (1)
Spain (3)
Beatriz Mothe, MD, PhD (1) · Jose R Arribas Lopez, Md, PhD (1)